Stifel Nicolaus analyst Derek Archila maintained a Buy rating on NGM Biopharmaceuticals (NGM) today. The company’s shares closed last Friday at $28.38.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 7.2% and a 44.6% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for NGM Biopharmaceuticals with a $43.75 average price target, which is a 50.2% upside from current levels. In a report issued on May 10, Chardan Capital also reiterated a Buy rating on the stock with a $44.00 price target.
See today’s analyst top recommended stocks >>
Based on NGM Biopharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $21.58 million and GAAP net loss of $27.54 million. In comparison, last year the company earned revenue of $24.36 million and had a GAAP net loss of $19.12 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration. The company was founded by Jin-Long Chen in 2008 and is headquartered in South San Francisco, CA.
